COVID-19 Disease Clinical Trial
Official title:
The Predictive Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease- A Retrospective Study
To investigate the predictive role of lymphocyte subsets and other laboratory measurements in adult patients with COVID-19.This was a single center, retrospective study that involved adult patients with confirmed diagnosis of COVID-19. Electronic medical records were reviewed. Data including age, sex, symptom from onset to hospital admission and laboratory findings at admission of hospitalized patients with confirmed COVID-19 were extracted and analyzed retrospectively.This study indicates that the levels of lymphocyte subsets (CD4+, and CD8+) are associated with disease progression and severity, along with prognosis in patients with COVID-19.
This was a single center, retrospective study that involved adult patients with confirmed diagnosis of COVID-19. Electronic medical records were reviewed. Data including age, sex, symptom from onset to hospital admission and laboratory findings at admission of hospitalized patients with confirmed COVID-19 were extracted and analyzed retrospectively. Identifying the possible immune factors and laboratory parameters is requisite for the early identification of patients with severe COVID-19 and timely intervention for control of the disease. There is an unmet need to establish robust clinical cutoffs of lymphocyte subsets for predicting risk associated with ICU admission, mechanical ventilation, and mortality in COVID-19 patients. This retrospective study was thus carried out to improve knowledge and clinical utility of lymphocyte subset measurements, together with other laboratory measurements and clinical information, for understanding prognosis in COVID-19 patients. These findings suggest that alterations in lymphocyte subsets and laboratory measurements play a significant role in the progression of COVID-19. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04984408 -
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
|
Phase 3 | |
| Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04587323 -
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
|
||
| Completed |
NCT04682873 -
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
|
Phase 3 | |
| Completed |
NCT04359212 -
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
|
||
| Completed |
NCT05603130 -
Epidemiologic Register on Diabetes and COVID-19 in Tunisia
|
||
| Completed |
NCT04830800 -
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC
|
Phase 1/Phase 2 | |
| Completed |
NCT04757792 -
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
|
||
| Active, not recruiting |
NCT04417257 -
Study of LAU-7b for the Treatment of COVID-19 Disease in Adults
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04522037 -
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
|
||
| Completed |
NCT04446377 -
A Study of LAM-002A for the Prevention of Progression of COVID-19
|
Phase 2 | |
| Active, not recruiting |
NCT04969172 -
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
|
Phase 2 | |
| Completed |
NCT04366024 -
A Novel Nomogram to Predict Severity of COVID-19
|
||
| Completed |
NCT04347369 -
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
|
||
| Completed |
NCT04787510 -
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
|
||
| Completed |
NCT05329220 -
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
|
Phase 3 | |
| Active, not recruiting |
NCT05077267 -
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
|
Phase 2 | |
| Completed |
NCT04472013 -
Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
|
||
| Active, not recruiting |
NCT04371354 -
Outcomes of Covid-19 Protective Measures in Endoscopy
|